An academic CRO, built where research happens.
ACRO bridges academic research and industry sponsors with biostatistics depth, quantitative pharmacology, and oncology Phase 1 advisory — anchored at a research-intensive university hospital.
An academic CRO, built where research happens.
ACRO Inc. (Academic Contract Research Organization) is a Korean CRO embedded within a research-intensive university hospital. We focus on oncology Phase 1 advisory and quantitative pharmacology — combining hospital-level research access with biostatistics depth shaped by national cohort governance and academic research culture.
We operate as a strategic and methodological partner to sponsors and investigators, with three connected pillars: Clinical Solutions for trial design and regulatory pathway support, Research Solutions for evidence generation and publication, and Bio & Medical Intelligence for R&D and policy advisory.
Our work spans Korean and international development programs, with academic university partnerships and a Korea–US bridging collaboration.
How ACRO took shape
A newly established Academic CRO — built on a clear founding intent and a working R&D foundation from day one.
ACRO Inc. established
Founded as an Academic Contract Research Organization to bridge Korean hospitals and global bioscience clusters — combining academic rigor with practical clinical research expertise.
In-house R&D Institute established
Government-recognized corporate R&D institute registered — formalizing ACRO's methodological and research capability as a standing research function.
Built on integrity, passion, and collaboration — bridging Korean research and the global bioscience ecosystem.
Connecting the global research ecosystem.
ACRO works as a bridge between Korean hospitals and global bioscience clusters. Through networks with the world's leading bio hubs, we help Korean researchers contribute on the international stage — strengthening Korea's access to global innovation, clinical capability, and new research opportunities.
Turning your hypothesis into success.
From a researcher's idea to academic and commercial success, ACRO accompanies every step. From preclinical data through publication and commercialization, we combine academic rigor with practical expertise to maximize the probability of research success — not an outsourcing vendor, but a strategic partner designing success alongside you.
Academic rigor, practical expertise.
Sponsors get peer-reviewable evidence. Investigators get methodological partnership. Hospitals and academic societies get research infrastructure and statistical depth they can rely on — held together by CDISC standards and a single methodological backbone.
Integrity
Highest standards of research ethics and methodological transparency. Pre-specified analyses, honest reporting, documentation that would withstand audit.
Passion
Genuine investment in our clients' research outcomes — the curiosity and care of an academic partner, applied with the discipline of an industry team.
Trust
Long-term partnerships built on consistent delivery, methodological honesty, and the kind of reliability that earns repeat engagement.
Collaboration
Hospitals, academic societies, sponsors, and investigators all working on the same evidence backbone — methodology that crosses institutional lines.
The people behind ACRO
A focused team bringing together biostatistics, clinical pharmacology, regulatory science, and oncology research — anchored by academic backgrounds from Korea's leading universities.
Collaborations
Quantitative methodology
ESS, PSM, MAIC, informative censoring, BOIN and other dose-finding designs, ICH E9(R1) estimand framework.
Model-Informed Drug Development
Population PK, exposure–response analysis, FDA Project Optimus and ICH M12 alignment, NONMEM and Monolix-based modeling.
Advisory across major indications
AML/FLT3, ES-SCLC, NPC, HNSCC, CRC — Phase 1 design, dose optimization, and real-world evidence generation.
Multi-region pathway advisory
MFDS, FDA, EMA, and TGA (Australian CTN) pathway advisory; pre-IND and MIDD meeting preparation.
CDISC standardization & RWD
CDISC Tabulation certified expertise. SDTM and ADaM mapping, Define-XML, Korean RWD infrastructure (K-CURE, NHIS, HIRA).
Publication & regulatory writing
Protocols, IBs, CSRs, manuscripts, and conference abstracts — written with statistical and regulatory inputs integrated from the first draft.